[4]
Sessa B. The history of psychedelics in medicine Handbuch Psychoaktive Substanzen Springer Reference Psychologie. Berlin: Springer 2016.
[5]
Sessa B. The psychedelic renaissance: Reassessing the role of psychedelic drugs in 21st century psychiatry and society. Muswell Hill Press, United Kingdom 2012.
[8]
Samorini G. Mushroom effigies in world archaeology: from rock art to mushroom-stonesThe stone mushrooms of Thrace EKATAIOS. Alexandroupoli 2012; pp. 16-44.
[10]
Hofmann A. Teonanácatl and Ololiuqui, two ancient magic drugs of Mexico. Bull Narc 1971; 23(1): 3-14.
[11]
Schultes RE, Hofmann A. Plants of the gods: origins of hallucinogenic use. New York: McGraw-Hill 1979.
[12]
Stein DL. Psychedelics and the ancient Near East. Astor Blog 2010.
[13]
Spath E. Ueber die Anhalonium-Alkaloide. I. Anhalin and Mezcalin Monatsh Chem 1919; 40: 129-52.
[17]
Hofmann A. LSD: my problem child (c)1980 by McGraw-Hill Published by McGraw-Hill Book Company ISBN 0-07-029325-2.
[18]
Stall WA. LSD, ein Phantastikum aus der Mutterkorngruppe. Schweizer Archiv fur Nelirologie and Psychiatric 1947; 60: 279.
[19]
Condrau G. Clinical experiences in mental patients with lysergic acid diethylamide. Acta Psychiatr Neurol 1949; 24(9)
[20]
Bush AK, Johnson WC. LSD-25 as an aid in psychotherapy. Dis Nerv Syst 1950; 11: 241-53.
[25]
Ling TM, Buckman J. Lysergic Acid (LSD 25) & Ritalin in the Treatment of Neurosis. Lambarde Press 1963.
[26]
Grinspoon L, Bakalar JB. In: Psychedelic drugs reconsidered. New York: Basic Books 1979.
[27]
Shulgin AT, Shulgin A. 2C-I; 2, 5-dimethoxy-4-iodophenethylamine PiHKAL—a chemical love story. Berkeley: Transform Press 1991; pp. 539-42.
[28]
Ingrasci R. Testimony for MDMA hearing submitted by Richard Ingrasci, MD, MPH In the matter of MDMA scheduling 1985.
[30]
Lotsof HS. Ibogaine in the treatment of chemical dependence disorders: Clinical perspectives. MAPS Bulletin 1995; 3: 16-27.
[31]
Grof S. LSD psychotherapy. místo neznámé. (2001): 978-0966001945.
[54]
Hollister LE. Effects of hallucinogens in humans. New York: Raven Press 1984; pp. 19-33.
[55]
Grob CS, McKenna DJ, Callaway JC, et al. Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. J Nerv Ment Dis 1996; 184(2): 86-94.
[63]
Huxley A. The doors of perception. Mental (Barbacena) 1952; 98: 2-4.
[64]
Goodman A, Gilman A. Drug addiction and drug abuse. The pharmacological basis of therapeutics 1990.
[76]
Göőz M, Göőz P, Luttrell LM, Raymond JR. 5-HT2A receptor induces ERK phosphorylation and proliferation through ADAM-17 tumor necrosis factor-α-converting enzyme (TACE) activation and heparin-bound epidermal growth factor-like growth factor (HB-EGF) shedding in mesangial cells. J Biol Chem 2006; 281(30): 21004.
[78]
Goodman LS. Goodman and Gilman’s the pharmacological basis of therapeutics. New York: McGraw-Hill 1996.
[87]
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). American Psychiatric 2013.
[103]
Gouzoulis-Mayfrank E, Hermle L, Thelen B, Sass H. History, rationale and potential of human experimental hallucinogenic drug research in psychiatry. Pharmacopsychiatry 1998; 31(S 2): 63-8.
[105]
Arora RC, Meltzer HY. Serotonin 2 (5-HT 2) receptor binding in the frontal cortex of schizophrenic patients. J Neural Transm Gen Sect 1991; 85(1): 19-29.
[147]
Johansen PØ, Krebs TS. How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale. J Psychopharmacol 2009; 23(4): 389-91.
[165]
Grob CS, Bossis AP, Griffiths RR. Use of the classic hallucinogen psilocybin for treatment of existential distress associated with cancer. 1Psychological aspects of cancer 2013; 291-308.
[169]
Javidi H, Yadollahie M. Post-traumatic stress disorder. Int J Occup Environ Med 2012; 3: 2-9.
[189]
Alper KR, Lotsof HS. The use of ibogaine in the treatment of addictions. New evidences for hallucinogenic substances as treatments 2007; 2: 43-65.
[198]
Jones SA, O’Kelly A. Psychedelics as a Treatment for Alzheimer’s Disease Dementia. Front Synaptic Neurosci 2020; 12: 34.
[225]
Kvam TM, Stewart LH, Andreassen OA. Psychedelic drugs in the treatment of anxiety, depression and addiction. Tidsskrift for den Norske laegeforening: tidsskrift for praktisk medicin, ny raekke. 2018; 138(18)